Cumberland Pharmaceuticals Inc. (CPIX) intrinsic value & 10-year financials
Cumberland Pharmaceuticals Inc. (CPIX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 3.6% a year to $44.5M, with an average return on invested capital of -23.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $7.18
- Market cap
- $106.7M
- Revenue (FY2025)
- $44.5M
- Revenue growth (10-yr CAGR)
- 3.6%
- ROIC (10-yr avg)
- -23.9%
- Free cash flow (FY2025)
- $4.8M
CPIX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $44.5M | -$2.8M | -$0.19 | $4.8M | -6.3% | -17.0% |
| FY2024 | $37.9M | -$6.5M | -$0.46 | -$678.6K | -17.0% | -40.7% |
| FY2023 | $39.6M | -$6.3M | -$0.44 | $5.8M | -24.2% | -50.7% |
| FY2022 | $40.7M | -$5.6M | -$0.38 | $8.4M | -14.0% | -30.9% |
| FY2021 | $35.0M | -$3.5M | -$0.24 | $6.2M | -21.9% | -39.2% |
| FY2020 | $35.8M | -$3.3M | -$0.22 | $5.3M | -17.8% | -26.4% |
| FY2019 | $45.6M | -$3.5M | -$0.23 | $2.8M | -8.0% | -14.2% |
| FY2018 | $40.2M | -$7.0M | -$0.45 | $2.7M | -18.4% | -12.3% |
| FY2017 | $40.4M | -$8.0M | -$0.50 | -$833.7K | -10.1% | -5.9% |
| FY2016 | $32.5M | -$944.7K | -$0.06 | $438.6K | -4.4% | -1.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CUMBERLAND PHARMACEUTICALS INC has demonstrated mature, steady growth, with revenue compounding at 3.6% annually over the past decade.
CUMBERLAND PHARMACEUTICALS INC has historically struggled to out-earn its cost of capital, averaging just -23.9% ROIC.
CUMBERLAND PHARMACEUTICALS INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CUMBERLAND PHARMACEUTICALS INC is modeled at 3.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2.56 per share.